Changes in [H-3]zolpidem and [H-3]Ro 15-1788 binding in rat globus pallidus and substantia nigra pars reticulata following a nigrostriatal tract lesion

TY - JOUR

T1 - Changes in [H-3]zolpidem and [H-3]Ro 15-1788 binding in rat globus pallidus and substantia nigra pars reticulata following a nigrostriatal tract lesion

AU - Chadha, A

AU - Howell, O

AU - Atack, J R

AU - Sur, C

AU - Duty, S

PY - 2000/4/17

Y1 - 2000/4/17

N2 - Changes in GABA(A) receptor alpha(1) subunit gene expression occur in the globus pallidus and substantia nigra pars reticulata following lesions of the nigrostriatal tract. To determine whether these changes are translated at the protein level, we performed quantitative autoradiography with the alpha(1) selective ligand, [H-3]zolpidem, and the non-selective benzodiazepine site ligand, [H-3]Ro 15-1788. Binding of both [H-3]zolpidem and [H-3]Ro 15-1788 was significantly increased in the substantia nigra pars reticulata (13.5+/-4.1 and 26.3+/-2.9%, respectively) and significantly reduced in the globus pallidus (20.9+/-0.8 and 18.3+/-1.3%, respectively). These changes in alpha(1) subunit protein expression may help to compensate for the pathological changes in GABAergic activity that occur after striatal dopamine depletion. (C) 2000 Elsevier Science B.V. All rights reserved.

AB - Changes in GABA(A) receptor alpha(1) subunit gene expression occur in the globus pallidus and substantia nigra pars reticulata following lesions of the nigrostriatal tract. To determine whether these changes are translated at the protein level, we performed quantitative autoradiography with the alpha(1) selective ligand, [H-3]zolpidem, and the non-selective benzodiazepine site ligand, [H-3]Ro 15-1788. Binding of both [H-3]zolpidem and [H-3]Ro 15-1788 was significantly increased in the substantia nigra pars reticulata (13.5+/-4.1 and 26.3+/-2.9%, respectively) and significantly reduced in the globus pallidus (20.9+/-0.8 and 18.3+/-1.3%, respectively). These changes in alpha(1) subunit protein expression may help to compensate for the pathological changes in GABAergic activity that occur after striatal dopamine depletion. (C) 2000 Elsevier Science B.V. All rights reserved.

UR - http://www.scopus.com/inward/record.url?scp=0034678144&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(00)02081-3

DO - 10.1016/S0006-8993(00)02081-3

M3 - Article

SN - 1873-2747

VL - 862

SP - 280

EP - 283

JO - Brain Research

JF - Brain Research

IS - 1-2

ER -